Accelerating digital eye care to market

OKKO Health是一家总部位于布里斯托尔的眼科保健数字健康公司，该公司制作眼科专家可以开处方的医疗级应用程序，这样长期患有眼疾的人就可以在面对面预约之间安全地监测他们的视力。目前的产品用于治疗黄斑变性和糖尿病性眼病，这两种疾病在英国和发达国家都是可避免失明的主要原因。目前在医院或验光师/验光师就诊之间缺乏自我监测视力的能力，这意味着威胁视力的变化会在几周或几个月内被忽视，到那时治疗通常是无效的。在家庭视力监测的帮助下，患者将能够在出现问题时识别并及时寻求治疗，以保护他们的视力，并长期保持良好的视力。OKKO的应用程序将视觉科学融入到简单的视频游戏中，患者每周“玩”三次，以生成有关他们眼睛健康的数据，他们的眼科专家也可以远程检查。该项目旨在进一步开发该技术及其相关系统，以确保该技术安全、经济高效，并在未来几年惠及全球尽可能多的人。特别是，OKKO将升级他们的ce标志，开发一个可扩展的系统，允许不同国家的医生用不同的语言开处方，并了解基于证据和利益的定价结构，这将使OKKO成长为一家成功的公司，并在国际市场上获得NHS和私人保险等医疗服务提供者的报销。

OKKO Health is an eye care digital health company, based in Bristol, and making medical-grade apps that eye specialists can prescribe so that people who live with long-term eye disease can safely monitor their vision between in-person appointments.The current product is for macular degeneration and diabetic eye disease, which are both leading causes of avoidable blindness in the UK and in developed nations.The current lack of ability to self-monitor vision between any hospital or optometrist/optician visits means that sight-threatening changes go unnoticed for weeks or months, by which point treatment is often ineffective.With the help of home-monitoring of vision, patients will be able to identify when problems arise and seek prompt treatment to preserve their vision and keep seeing well into the long term.OKKO's app blends vision science behind simple video games, that the patient 'plays' 3 times weekly, in order to generate data about their eye health, that their eye specialist can also review remotely.This project is about further developing the technology and the systems around it, to ensure that this technology is safe, cost effective and can reach as many people as possible globally in the coming years. In particular, OKKO will upgrade their CE-mark, develop a scalable system that allows the product to be prescribed in different languages by doctors in different countries, and also understand the evidence and benefit-based pricing structure that will allow OKKO to grow as a successful company and be reimbursed by health providers like the NHS and private insurance in international markets.